Barclays’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-112,300
| Closed | -$2.42M | – | 5411 |
|
|
2025
Q4 | $2.42M | Sell |
112,300
-165,000
| -60% | -$3.48M | ﹤0.01% | 2797 |
|
|
2025
Q3 | $5.34M | Buy |
277,300
+165,000
| +147% | +$2.94M | ﹤0.01% | 2146 |
|
|
2025
Q2 | $1.92M | Buy |
+112,300
| New | +$4.79M | ﹤0.01% | 2882 |
|
|
2024
Q4 | – | Sell |
-50,300
| Closed | -$6.28M | – | 5465 |
|
|
2024
Q3 | $6.28M | Sell |
50,300
-5,000
| -9% | -$691K | ﹤0.01% | 1873 |
|
|
2024
Q2 | $8.74M | Buy |
+55,300
| New | +$7.1M | ﹤0.01% | 1249 |
|
|
2021
Q1 | – | Sell |
-19,800
| Closed | -$3.38M | – | 5152 |
|
|
2020
Q4 | $3.38M | Buy |
19,800
+9,000
| +83% | +$1.33M | ﹤0.01% | 1820 |
|
|
2020
Q3 | $1.52M | Hold |
10,800
| – | – | ﹤0.01% | 2340 |
|
|
2020
Q2 | $1.73M | Sell |
10,800
-111,600
| -91% | -$15.2M | ﹤0.01% | 2257 |
|
|
2020
Q1 | $12M | Sell |
122,400
-49,500
| -29% | -$5.66M | 0.01% | 892 |
|
|
2019
Q4 | $22.2M | Sell |
171,900
-7,300
| -4% | -$737K | 0.01% | 904 |
|
|
2019
Q3 | $13.5M | Sell |
179,200
-73,900
| -29% | -$8.73M | 0.01% | 1113 |
|
|
2019
Q2 | $38.5M | Buy |
253,100
+151,400
| +149% | +$18.4M | 0.02% | 581 |
|
|
2019
Q1 | $12.1M | Sell |
101,700
-300
| -0.3% | -$38.6K | 0.01% | 1115 |
|
|
2018
Q4 | $11.1M | Sell |
102,000
-8,300
| -8% | -$1.04M | 0.01% | 1090 |
|
|
2018
Q3 | $17.8M | Sell |
110,300
-98,300
| -47% | -$13.4M | 0.01% | 919 |
|
|
2018
Q2 | $27.6M | Buy |
208,600
+84,300
| +68% | +$7.95M | 0.02% | 625 |
|
|
2018
Q1 | $9.21M | Sell |
124,300
-65,300
| -34% | -$4.35M | 0.01% | 1217 |
|
|
2017
Q4 | $10.6M | Sell |
189,600
-65,200
| -26% | -$3.45M | 0.01% | 1156 |
|
|
2017
Q3 | $11.6M | Buy |
254,800
+163,100
| +178% | +$6.52M | 0.01% | 963 |
|
|
2017
Q2 | $3.09M | Buy |
91,700
+11,600
| +14% | +$378K | ﹤0.01% | 1856 |
|
|
2017
Q1 | $2.37M | Sell |
80,100
-591,500
| -88% | -$18.3M | ﹤0.01% | 1924 |
|
|
2016
Q4 | $18.4M | Sell |
671,600
-432,200
| -39% | -$17.4M | 0.02% | 635 |
|
|
2016
Q3 | $67.8M | Buy |
1,103,800
+649,000
| +143% | +$19.6M | 0.08% | 194 |
|
|
2016
Q2 | $8.67M | Buy |
+454,800
| New | +$8.42M | 0.01% | 917 |
|
|
2016
Q1 | – | Sell |
-233,000
| Closed | -$8.85M | – | 6416 |
|
|
2015
Q4 | $8.85M | Buy |
233,000
+144,200
| +162% | +$4.68M | 0.01% | 966 |
|
|
2015
Q3 | $2.84M | Buy |
88,800
+68,800
| +344% | +$2.33M | ﹤0.01% | 1817 |
|
|
2015
Q2 | $600K | Buy |
+20,000
| New | +$409K | ﹤0.01% | 3324 |
|
|
2015
Q1 | – | Sell |
-16,900
| Closed | -$237K | – | 7250 |
|
|
2014
Q4 | $237K | Hold |
16,900
| – | – | ﹤0.01% | 4504 |
|
|
2014
Q3 | $355K | Hold |
16,900
| – | – | ﹤0.01% | 4254 |
|
|
2014
Q2 | $490K | Hold |
16,900
| – | – | ﹤0.01% | 4001 |
|
|
2014
Q1 | $406K | Sell |
16,900
-90,000
| -84% | -$2.29M | ﹤0.01% | 4131 |
|
|
2013
Q4 | $2.14M | Sell |
106,900
-130,000
| -55% | -$3.86M | ﹤0.01% | 2603 |
|
|
2013
Q3 | $11.1M | Sell |
236,900
-361,000
| -60% | -$13.9M | 0.01% | 1068 |
|
|
2013
Q2 | $22.7M | Buy |
+597,900
| New | +$21.4M | 0.03% | 584 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
Barclays's SRPT Position: Q1 2026 in Review
Barclays reduced its Sarepta Therapeutics (SRPT) stake by 42% in Q1 2026, selling an estimated $1.88M and leaving 135,959 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2125.
Barclays first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $63.3M in Q2 2024. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Barclays held 135,959 shares of Sarepta Therapeutics worth $2.96M as of Q1 2026.
- Barclays sold 97,190 Sarepta Therapeutics shares in Q1 2026, an estimated $1.88M.
- Sarepta Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2125 holding.
- Barclays first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Barclays's Sarepta Therapeutics position peaked at $63.3M in Q2 2024.
- 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.